Burzynski Research Institute (Burzynski Research Institute) Investments And Advances : $0.00 Mil (As of Feb. 2024)

View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Investments And Advances?

Burzynski Research Institute's Investments And Advances for the quarter that ended in Feb. 2024 was $0.00 Mil.

Burzynski Research Institute Investments And Advances Historical Data

The historical data trend for Burzynski Research Institute's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Investments And Advances Chart

Burzynski Research Institute Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Investments And Advances

Get a 7-Day Free Trial

Burzynski Research Institute Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

Burzynski Research Institute Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Burzynski Research Institute (Burzynski Research Institute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

N/A

Address

9432 Katy Freeway, Houston, TX, USA, 77055

Website

http://www.burzynskiresearch.com

Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.

Executives

Monika Szopa-paszkowiak	director	9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff	director	9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski	director, 10 percent owner	9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood	director	9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski	officer: Secretary and Treasurer	9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski	director	9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki	officer: VP of Clinical Trials	9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll	director	9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski	director, 10 percent owner, officer: President	9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson	officer: Chief Financial Officer	9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines